Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2023 Aug 10;19(8):e1011553. doi: 10.1371/journal.ppat.1011553

Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: Phylogenetic analysis and intervention scenarios

Martina L Reichmuth 1,*,#, Emma B Hodcroft 1,2,3,#, Christian L Althaus 1,3
Editor: Shuo Su4
PMCID: PMC10443857  PMID: 37561788

Abstract

The SARS-CoV-2 pandemic has led to the emergence of various variants of concern (VoCs) that are associated with increased transmissibility, immune evasion, or differences in disease severity. The emergence of VoCs fueled interest in understanding the potential impact of travel restrictions and surveillance strategies to prevent or delay the early spread of VoCs. We performed phylogenetic analyses and mathematical modeling to study the importation and spread of the VoCs Alpha and Delta in Switzerland in 2020 and 2021. Using a phylogenetic approach, we estimated between 383–1,038 imports of Alpha and 455–1,347 imports of Delta into Switzerland. We then used the results from the phylogenetic analysis to parameterize a dynamic transmission model that accurately described the subsequent spread of Alpha and Delta. We modeled different counterfactual intervention scenarios to quantify the potential impact of border closures and surveillance of travelers on the spread of Alpha and Delta. We found that implementing border closures after the announcement of VoCs would have been of limited impact to mitigate the spread of VoCs. In contrast, increased surveillance of travelers could prove to be an effective measure for delaying the spread of VoCs in situations where their severity remains unclear. Our study shows how phylogenetic analysis in combination with dynamic transmission models can be used to estimate the number of imported SARS-CoV-2 variants and the potential impact of different intervention scenarios to inform the public health response during the pandemic.

Author summary

We were interested in quantifying the number of imports of SARS-CoV-2 variants of concern (VoCs) and assessing the potential impact of travel restrictions and surveillance strategies in Switzerland. We used genomic surveillance data to calculate when and how often two different VoCs, Alpha and Delta, were imported into Switzerland. We used these estimates to simulate the spread of VoCs in a transmission model and investigated counterfactual intervention scenarios. Even though there were hundreds to a thousand imports, implementing border closures following the announcement of VoCs would have had limited impact on delaying their spread. However, improved surveillance of travelers would be a more effective measure to delay the spread of VoCs. In conclusion, our study illustrates that phylogenetic analysis combined with mathematical transmission models can be used to inform the public health response during pandemics.

Introduction

Since 2019, the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has been spreading continuously, which has driven its evolution. Variants of concern (VoCs) have emerged which are associated with increased transmissibility, immune escape, changes in disease severity, or a combination thereof [1]. Alpha and Delta emerged in late 2020 and mid 2021, and their transmission dynamics were influenced by importations, the heterogeneous landscape of naturally acquired and vaccine-elicited immunity and non-pharmaceutical interventions (NPIs) such as surveillance of travelers and travel restrictions. It was previously shown that the resumption of travel in summer 2020 after strict control interventions which—while varying by country—often involved border closures, working from home and restricting social contacts, led to the importation of a new SARS-CoV-2 variant that fueled epidemics in countries with low-incidence [2,3]. In winter 2020/2021, Swiss authorities tightened travel restrictions again for travelers from the United Kingdom (UK) [4], which were followed by overall stricter measures in Switzerland once concerns about the newly detected Alpha variant were communicated. To date, however, the impact of such travel restrictions and surveillance strategies to prevent or delay the introduction of VoCs is not well understood.

Global genomic surveillance is vital to capture the transmission dynamics of different SARS-CoV-2 variants around the world. Genomic and epidemiological data allow characterization and quantification of the spread of VoCs [59]. At the end of 2020, deletions in the Alpha variant meant that Polymerase Chain Reaction (PCR) testing methods targeting a particular section of the S gene failed, leading to ‘S gene target failure’ (SGTF), which allowed tracking of the spread of Alpha, and in some cases, preferential sequencing of Alpha cases [7]. Alpha, which was initially detected in the UK, showed a 37%-100% increase in transmissibility over previously circulating variants [5,711]. In early 2021, Alpha was continuously displaced by another VoC, Delta, which likely emerged in India [12]. For Delta, studies have estimated an increased transmissibility compared to previously circulating variants, which were predominantly Alpha in Europe and North America, Beta in South Africa, and Gamma in South America, between 40% and 167% [8,9]. VoCs emerge in one place and spread to different countries through travel. Therefore, quantifying the impact of travel and imported SARS-CoV-2 cases can help guide pandemic responses, particularly prior to wide-spread vaccination. Routinely obtained surveillance data can provide valuable information about the place of exposure, but can be biased [13]. Leveraging the wealth of genomic data offers the opportunity to integrate an additional level of information to inform the impact of travel and importation events. To try to prevent or slow the import of VoCs, some countries have introduced travel restrictions such as vaccination certificates, testing, or travel bans. Although travel restrictions have not prevented the global spread of VoCs, they could potentially mitigate the early spread and lessen the impact of new VoCs on hospitalizations and deaths until there is an improved understanding of new VoCs to then intervene appropriately.

Mathematical modeling studies and phylogenetic analyses are central to understand the transmission dynamics and evolution of infectious diseases and to inform public health decision making [14]. For example, the early description of the emergence of Alpha was based on mathematical and statistical modeling approaches and critically influenced the early response against the variant [10]. Phylodynamic analyses have been used to study the evolution of infectious pathogens in intra- and inter-host systems [15,16]. For example, BEAST [17] can be combined with compartmental transmission models to infer epidemiological parameters such as the basic reproduction number R0 [18,19]. Inter-host epidemiological dynamics have also been used to study the importation of infectious pathogens such as Zika virus, dengue virus or SARS-CoV-2 [3,6,2026]. Integrating phylogenetic analyses with dynamic transmission models also has the potential to provide comprehensive inferences and projections of the SARS-CoV-2 pandemic.

In this study, we used a stepwise approach of phylogenetic analyses in combination with a dynamic SARS-CoV-2 transmission model to study the spread of VoCs in Switzerland. First, we reconstructed phylogenies of the Alpha and Delta variants to estimate the number of imported cases into Switzerland. Second, we modeled the importation and spread of Alpha and Delta in Switzerland. Finally, we simulated the impact of three counterfactual scenarios to mitigate the spread of Alpha and Delta.

Methods

Data

We used publicly available data from the Swiss Federal Office of Public Health (FOPH), CoV-Spectrum, and the Federal Statistical Office (FSO) on daily laboratory-confirmed SARS-CoV-2 cases, daily estimates of the effective reproduction number (Re), genomic metadata, and the population size [2732]. We accessed sequencing data via GISAID [33] on 15 February 2022, including data generated in Switzerland as part of a federal consortium [34], to ensure the considered sequences encompass the introduction periods of Alpha and Delta into Switzerland. We used a combination of code from CoVariants.org and in-house scripts (available at https://github.com/emmahodcroft/Intros-CH-AlphaDelta) to select all Alpha (Nextstrain clade 20I) and Delta (Nextstrain clades 21A, 21I, and 21J) sequences sampled in Switzerland prior to 31 March 2021 and 31 July 2021, respectively, which are the dates when the proportion of each VoC was over 90% among all sequenced cases in Switzerland. We then ran the selected sequences through the Nextstrain ncov pipeline [35], as modified for CoVariants.org, to generate ‘focal’ phylogenies (available at https://github.com/emmahodcroft/ncov_2021/tree/random_context_reduce). We minimized bias and improved phylogenetic inference by masking highly homoplastic sites and removing sequences with fewer than 27,000 bases, as recommended by de Maio et al. (2020) [36]. These focal trees contained all Alpha or Delta sequences from Switzerland before the 90% VoC representation date which passed quality control criteria. Alongside these, to maximize the chance of including closely-related non-Swiss sequences, which allows detection of a putative importation, we included up to 10,000 non-Swiss, global ‘context’ sequences that were most genetically similar to our focal set. We chose the number of genetically similar sequences in order to have a dataset of approximately 15,000 to 18,000 sequences for computational tractability, while resulting in 1.25 to 2 genetically similar global sequences per focal sequence. In addition, approximately 200 random ‘background’ sequences, distributed through time, were included to ensure the tree rooted correctly. Both of these context and background sequence sets were generated using the algorithms in the Nextstrain ncov pipeline (see Method in S1 File), and were also sampled prior to 31 March 2021 and 31 July 2021 for Alpha and Delta respectively. The final set of sequences that we used for the analysis can be seen on GISAID under EPI_SET_221003xn (S1 Table); 93% of the Swiss sequences are also available openly (S2 Table). As a sensitivity analysis, we randomly down-sampled all available non-Swiss sequences prior to our cutoff dates by 50% before selecting the most 10,000 genetically similar sequences, and repeated this ten times. The objective was to assess the influence of context sequencing coverage on our phylogenetic analysis and estimates of the imports.

Phylogenetic analysis

To estimate the number of imports of VoCs into Switzerland, we collapsed phylogenetic trees into clusters. As previously described in Hodcroft et al. [3], we collapsed subtrees that contain only sequences from a single country into the parental node to form a polytomy. This process was repeated in a recursive ‘bottom-up’ fashion, such that every node eligible for collapsing was collapsed. After collapsing, we labeled internal nodes by the proportion of the geographic origin of their direct children (see Method in S1 File for a more detailed explanation). Because both Alpha and Delta originated outside of Switzerland, the roots of these variants are non-Swiss, and thus, we inferred a putative import whenever a node without Swiss sequences led to a node with Swiss sequences. We used two approaches to estimate the number of imports, referred to as the liberal and conservative phylogenetic approach, which infer upper and lower bounds on the number of imports. The liberal approach considered any mixed Swiss and non-Swiss node as an introduction (Fig 1A). On the other hand, when Swiss and non-Swiss sequences formed a subtree (with mixed-country nodes leading to more mixed-country nodes), the conservative approach counted all directly linked mixed-country nodes as only one import, with further non-Swiss sequences assumed to originate from parallel evolution outside of Switzerland or exports from Switzerland (Fig 1B). Import events are recorded and were then used to parameterize the transmission model (see next section about the transmission model).

Fig 1. Illustrative example of the conservative and liberal approach to estimate the importation of SARS-CoV-2 variants of concern (VoC) to Switzerland.

Fig 1

A: In the liberal approach, each subsequent subtree of only Swiss sequences is considered as a separate importation event. In this example, there would be two imports to Switzerland. B: In the conservative approach, subtrees with mixed Swiss and non-Swiss sequences are considered as one importation. Non-Swiss sequences are assumed to be exports from Switzerland or to originate from parallel evolution outside of Switzerland. In this example, there would be one import into Switzerland. More details are provided in the Method in S1 File.

The liberal approach may overestimate imports, as further exports from Switzerland to other countries or diversification within Switzerland could be wrongly considered imports. In contrast, the conservative approach considered only the earliest clusters with a Swiss sequence as imports, which means that further potential imports were strictly excluded. We chose the date of the earliest sequence of a cluster as the import date and shifted the date backwards by seven days to account for the delay from infection to case reporting, i.e., lag of detection. In a sensitivity analysis, we used a range of three to thirteen days for the lag of detection derived from du Plessis et al. (2021) [6] (Fig D in S1 File). All code used to identify the selected sequences, to analyze the resulting phylogenies, to estimate the number of imports, and for the phylogenetic builds can be found on GitHub: github.com/emmahodcroft/Intros-CH-AlphaDelta.

Transmission model

Deterministic model

We used a deterministic, population-based transmission model for SARS-CoV-2 in Switzerland that was described by the following set of ordinary differential equations (ODEs) (Fig 2):

dS/dt=βtSI1(1+κ)βtSI1ωt,
dE1/dt=βtSI1σE1,
dE2/dt=(1+κ)βtSI2σE2+ωt,
dI1/dt=σE1γI1,
dI2/dt=σE2γI2,
dC1/dt=εγI1ζC1,
dC2/dt=εγI2ζC2,
dR1/dt=(1ε)γI1+ζC1,
dR2/dt=(1ε)γI2+ζC2,

where susceptible individuals S can get infected by individuals that either carry the pre-circulating variant (I1) or the imported VoC (I2) at rates βt and (1+κ)βt, respectively. κ denotes the increased transmissibility of the imported VoC. We calculated κ from the estimated growth advantage ρ of the new VoC compared to the previously circulating variants using a logistic growth model (binomial regression) for the proportion of the new variant among all previously circulating variants (Fig E in S1 File). Assuming no change in the generation time D and no immune evasion, κ = ρD/Rw [11], where Rw is the effective reproduction number of the previously circulating variants during the time period of replacement. We sampled from that the publicly available estimates of the daily overall effective reproduction number Re from 1 November 2020 to 31 January 2021 (early growth phase of Alpha) and from 1 April 2021 to 30 June 2021 (early growth phase of Delta), assuming the values correspond to Rw during these time periods (https://github.com/covid-19-Re) (Fig 3B) [28]. Additionally, we sampled from the estimated ρ and calculated the median κ. We then expressed the time-dependent transmission rate as a function of the overall Re as follows:

βt=ReS(1+pκ)γ

where p = E2/(E1+E2) corresponds to the proportion of the imported VoC. Exposed individuals E1 and E2 move through an incubation period at rate σ before they become infectious individuals I1 and I2 for 1/γ days. A fraction ε of infected infectious individuals enter a testing compartment where they get tested at rate ζ before entering the recovered compartment, whereas the remainder (1−ε) does not get tested and moves directly from the infected compartment to the recovered compartment. ωt corresponds to the time-dependent rate of importation of VoCs. We parameterized the vector ωt using the daily number of estimated imports from the phylogenetic analysis (Fig 4A and 4B), e.g., ωt for Alpha on 1 February 2021 was 8 and 2 for the liberal and conservative approach, respectively.

Fig 2. Scheme of the SARS-CoV-2 transmission model.

Fig 2

The model includes individuals that are susceptible (S), exposed to the pre-circulating variant (E1) or the imported VoC (E2), infected with the pre-circulating variant (I1) or the imported VoC (I2), tested (C1, C2), and recovered from infection (R1, R2). ωt denotes the importation of VoC as derived from the phylogenetic analysis.

Fig 3. SARS-CoV-2 epidemic in Switzerland from October 2020 to September 2021.

Fig 3

A: Number of laboratory-confirmed SARS-CoV-2 cases per day. B: Effective reproduction (Re) number of SARS-CoV-2 in Switzerland.

Fig 4. Dynamics of Alpha and Delta importation to Switzerland.

Fig 4

A, B: Number of imports estimated with the phylogenetic analysis. C, D: Number of laboratory-confirmed SARS-CoV-2 cases per day (gray). The black lines show the overall simulated number of reported cases. The blue and purple line show the simulated number of VoC cases. E, F: Proportion of reported Alpha and Delta among all SARS-CoV-2 infections. Gray: Genomic surveillance data. Blue: Liberal approach. Purple: Conservative approach.

We simulated importation of Alpha and Delta to Switzerland during the period from 1 October 2020 to 1 May 2021 and 1 February 2021 to 1 September 2021. We designated variants as either ‘Alpha’, ‘Delta’ or ‘other variants’ and the mathematical modeling analyses started on 1 October 2020 for Alpha and 1 February 2021 for Delta and ended on 1 May and 1 September, respectively. The initial state variables and the model parameters were informed by the literature, demography, estimates, and assumptions (Table 1). The initial number of recovered individuals infected with all previously circulating variants was informed by the Corona Immunitas study and set to 15% and 25% of the overall population for 1 October 2020 and 1 February 2021, respectively [37]. The initial numbers of exposed and infectious individuals infected with previously circulating variants were based on the number of laboratory-confirmed SARS-CoV-2 cases, the ascertainment rate, and the infectious period. The initial number of exposed and infectious individuals infected with the respective VoCs was set to zero. All other state variables, unless otherwise specified, were set to zero. Model simulations were performed in R (version 4.0.3) and code files are available on the following GitHub repository: github.com/ISPMBern/voc_imports_ch.

Table 1. Parameter values of the SARS-CoV-2 transmission model.
Model parameter Description Value Source
N Population size 8,644,780 Swiss FOPH [27]
R e Effective reproduction number Fig 3B Huisman et al. [28]
β t Transmission rate of previously circulating variant ReS(1+pκ)γ Based on Re, where p = E2/(E1+E2) corresponds to the proportion of the imported VoC
κ Increased transmissibility of VoC Alpha: 41%
Delta: 56%
Estimated from genomic data [31]
1/σ Incubation period 2.6 days Based on a generation time of 5.2 days [30]
1/γ Infectious period 2.6 days Based on a generation time of 5.2 days [30]
1/ζ Testing delay 2 days Assumption
ω t Rate of importation of VoCs Fig 4A and 4B Based on the phylogenetic analysis
ε Ascertainment rate 50% Informed by Stringhini et al. [38,39]

Abbreviations: FOPH, Federal Office of Public Health; VoC, variant of concern.

Counterfactual scenarios

We evaluated the potential impact of different intervention strategies to mitigate the spread of VoCs in Switzerland in various counterfactual scenarios:

  1. Existing border closure: We assumed that borders were already closed at the time of the first estimated import. We then simulated the opening of borders 1 to 100 days after the first estimated import and introduced imports as estimated from the phylogenetic analysis from that date forward.

  2. Implemented border closure: We assumed that borders were closed on the day of the international warning about the VoCs. For Alpha and Delta, we stopped imports for 1 to 60 days after 16 December 2020 and [40] 24 May 2021 [41], respectively.

  3. Increased surveillance of travelers: We assumed improved surveillance, quarantine, and isolation of travelers. We performed simulations where we reduced the number of simulated imports by randomly selecting 1 to 99% of the estimated imports from the phylogenetic analysis.

We calculated the time to dominance (>50%) of the VoC and compared it to the time to dominance as observed in Switzerland. Counterfactual scenarios that did not reach dominance within the predefined period were excluded from the analysis.

Stochastic model

We used a generic branching process model to investigate the impact of stochastic effects during the early growth phase of variants. The model accounts for superspreading of SARS-CoV-2 and simulates epidemic trajectories with 1, 10, and 100 seeds, which can be interpreted as imports. The branching process was based on a negative binomial distribution to describe the number of secondary cases, with a mean corresponding to Re and overdispersion parameter k [13,42,43]. The generation time was sampled from the gamma distribution with a mean of 5.2 days and a standard deviation of 1.72 days [30]. For Re of the variant, we randomly drew 104 values from a uniform distribution between 1.05 to 1.15. For each seeding scenario, we simulated 104 epidemic trajectories.

Results

In autumn 2020, the effective reproduction number Re of SARS-CoV-2 increased substantially which led to a rapid exponential increase in laboratory-confirmed cases in Switzerland (Fig 3A and 3B). In the following weeks and months, cantonal and federal authorities strengthened control measures that led to a reduction of Re (Fig F(A) in S1 File). On 16 December 2020, researchers in the UK announced a newly discovered SARS-CoV-2 variant with a potentially increased transmissibility (Alpha). In response to these findings, the Swiss federal authorities introduced travel restrictions to travelers from the UK [4] and increased sequencing coverage of SARS-CoV-2 (Figs F(B) and F(C) in S1 File). Nevertheless, Alpha then replaced the previously circulating variants during a period of high incidence from January to March 2021, pushing Re above 1 again. Based on genomic sequencing, we estimated that Alpha reached dominance (>50%) in Switzerland on 5 February 2021. In May 2021, Delta was identified as a new VoC. Subsequent growth of Delta in June and July 2021 led to an increase of laboratory-confirmed SARS-CoV-2 cases during summer 2021. We estimated that Delta reached dominance in Switzerland on 27 June 2021. The simulated timing of dominance lagged estimates from sample data more for Alpha than for Delta, which might have been influenced by missing early imports indicated by larger clusters for Alpha than for Delta at the beginning (Fig G in S1 File).

We estimated the number of Alpha and Delta importations to Switzerland using two phylogenetic approaches. The Alpha tree contained 7,988 Swiss Alpha sequences, 9,901 non-Swiss context sequences, and 162 background sequences. The Delta tree contained 5,210 Swiss Delta sequences, 9,973 non-Swiss context sequences, and 147 background sequences. Using the liberal approach, we found 1,038 and 1,347 imports of Alpha and Delta into Switzerland, respectively (Fig 4A and 4B and Table A in S1 File). With the conservative approach, we found 383 and 455 imports of Alpha and Delta into Switzerland, respectively. In our sensitivity analysis where we removed half of the available non-Swiss sequences before identifying the most genetically similar sequences to our Swiss sequences, the liberal and conservative approach had similar results as using the baseline sampling method (Fig H in S1 File).

We then introduced these estimated imports in the deterministic SARS-CoV-2 transmission model, which resulted in 593,418 and 592,768 simulated reported cases from 1 October to 1 May with the liberal and conservative approach, respectively, compared to 606,575 cases reported by the FOPH (Fig 4C and Table A in S1 File). For 1 February to 1 September, we simulated 288,397 and 271,702 SARS-CoV-2 cases with the liberal and conservative approach, respectively, compared to 260,933 cases reported by the FOPH (Fig 4D and Table A in S1 File).

To better understand the dynamics of VoCs replacing previously circulating variants, we estimated the time VoCs reached dominance. With the liberal approach, Alpha reached 50% of all infections on 5 March 2021 and Delta reached 50% on 30 June 2021 (Fig 4E and 4F). With the conservative approach, dominance was reached somewhat later, namely on 22 March 2021 and 9 July 2021, respectively. Compared to genomic monitoring data, the model lagged 28 to 45 days behind for Alpha and 3 to 12 days behind for Delta, respectively. This suggests that either the liberal approach better approximates the true number of imported cases that resulted in subsequent transmission chains, that certain events during the early phase of importation accelerated the growth of VoCs, or both. Stochastic simulations of imported variants highlight that the expected variation in the early growth phase can shift the epidemic trajectories by several weeks (Figs I(A) and I(B) and I(C) in S1 File).

We investigated different counterfactual scenarios to assess the impact of border closures and increased surveillance of travelers on the early spread of VoCs. Existing border closures at the time of the first estimated import could delay the time to dominance from a few days to several weeks (Fig 5A). Longer border closures result in increasing returns, e.g., doubling the time of closed borders from 50 to 100 days increases the time to dominance roughly 4-fold. Complete border closure for 100 days delayed the time to dominance by around 40 days. The effect of closed borders is substantially reduced when implemented after the international warning (Fig 5B). Increased surveillance of travelers that reduces the number of imported VoCs that result in a subsequent transmission chain by 25%, 50%, and 75% would delay the time to dominance of Alpha for 4, 10, and 19 days (95% compatibility interval (CI): 2–6, 7–14, and 13–28 days) and of Delta for 3, 6, and 14 days (95% CI: 2–5, 5–10, and 8–18 days) (Fig 5C).

Fig 5. Counterfactual scenarios for mitigating the spread of VoCs in Switzerland.

Fig 5

A: Existing border closure. B: Implemented border closure after warning about VoC. C: Increased surveillance of travelers.

Discussion

We used a combination of phylogenetic analysis and dynamic transmission modeling to estimate the number of imported VoCs and simulate the impact of counterfactual intervention scenarios in Switzerland. In the phylogenetic analysis, we found that single importation events happened early and at least several hundred Alpha (383–1,038) and Delta (455–1,347) cases were introduced into the Swiss SARS-CoV-2 epidemic during the study period. The actual number of imports is likely between these estimates. From our sensitivity analysis, we saw that even if there had been substantially less sequencing outside of Switzerland to help infer imports, we would still detect around the same number of introductions. The integration of these importation events into a transmission model accurately described the subsequent spread of VoCs. We estimated a 41% and 56% increased transmissibility of Alpha and Delta compared to previously circulating variants, which is in the range of previously reported estimates [5,711]. Applying our transmission model using counterfactual intervention scenarios showed that only very strict or existing control measures would substantially delay the time to dominance of VoCs. In contrast, implementing border closures after international warnings delayed the time to dominance of VoCs by a few days only. Increased surveillance of travelers—which is less disruptive than border closures—could prove effective for delaying the spread of VoCs in situations where their severity remains unclear. These findings have important implications for informing intervention strategies in the case of newly emerging SARS-CoV-2 VoCs and future pandemic preparedness.

The major strength of our study is the combination of phylogenetic analyses with a dynamic transmission model. This not only allowed us to estimate the number of imports but also to investigate counterfactual intervention scenarios. Our phylogenetic approach to estimate imported variants is standardizable and thus applicable to other countries with similar genomic surveillance and other emerging pathogens.

Our study also has a number of limitations. First, we used a deterministic transmission model for our main analysis and ignored the potential effects of stochasticity during the importation and early growth phase of VoCs. In the model, we assumed that all imported VoCs enter a deterministic growth trajectory. In contrast, some imported VoCs might not result in continuous transmission chains and go extinct even with Re > 1. We showed that stochastic effects during importation and the early growth phase can cause a variation in the time to dominance of several weeks. With the phylogenetic analysis, we found sufficiently large transmission clusters and imports of VoCs that were successfully established in the local population. Second, we fixed the generation time for Alpha, Delta, and earlier circulating variants to 5.2 days. There is some evidence that the generation time of Delta is somewhat shorter [44], but we do not expect this to affect our results substantially. Third, we did not consider the importation of other variants that could compete with the new VoCs. Since the new VoCs were characterized by an increased transmissibility, we do not expect this assumption to substantially affect the dynamics of the new VoCs replacing previously circulating variants. Fourth, we did not consider co-infection with different variants [45]. As we focus our analysis on the spread of VoCs and not on their evolution, we do not expect this to affect our results substantially. Fifth, we assumed a constant ascertainment of SARS-CoV-2 infections of 50%, which was informed by seroprevalence studies [38,39]. During the study period, test positivity varied and ascertainment might have fluctuated as well. Thus, our transmission model cannot precisely describe the overall number of infections, which was not the objective of our study. In addition, the high variation in genomic sequencing among different countries can influence the estimated number of imports from the phylogenetic analysis. For example in Switzerland the sequencing coverage increased from 2% in December 2020 (just after the first importation of Alpha) to 10% in April 2021 (during the first importation of Delta) [46,47], and was on average 14% for our study period (1 October 2020 to 1 September 2021). The limited sequencing efforts during the introduction of the Alpha variant may hinder the detection of early imports and splitting clusters accurately. Sixth, the lag time of detecting an import and the true introduction might vary by testing and sequencing strategies, e.g., du Plessis et al. (2021) reported a detection lag of 3 to 13 days of the introduced cluster time of the most recent common ancestor (TMRCA) to the true importation [6]. Finally, the phylogenetic analysis has intrinsic limitations due to the fact that not every infection is detected or sequenced, and interpretation during outbreaks requires caution [2,48], which was also highlighted at the beginning of the pandemic by Morel et al. 2020 [49]. This is specifically true for Alpha, which appeared at the end of 2020, prior to sequencing in Switzerland being scaled up considerably during 2021. To further mitigate the impact of sequencing error and unreliable sequences, as highlighted by Turakhia et al. (2020) [50], we excluded sequences with poor coverage and low quality control scores and masked homoplastic sites. There is currently no gold standard for estimating imports. Uncertainty in creating and interpreting phylogenies can lead both to imports being underestimated due to considering only one importation event per cluster and overestimated due to within-country diversification or further exports. In our analysis, we aimed to address this issue by using two approaches to estimate lower and upper bounds on the number of imports. The liberal approach considered any cluster containing Swiss sequences as an importation event. If the sequencing coverage was low, the liberal approach would thus overestimate imports and exports could cause Swiss sequences to be falsely classified as imports. In contrast, the conservative approach considered only the earliest clusters with Swiss sequence as imports, which means that further potential imports were strictly excluded.

For monitoring the transmission dynamics of SARS-CoV-2, it is important to differentiate between locally-acquired and imported infections, particularly in situations when the local incidence of infections is low [13]. Tomba and Wallinga (2008) emphasized the significance of estimating the impact of travel on infectious disease transmission and the potential effectiveness of interventions on the local spread, particularly highlighting that initial importation events will eventually lead to a local epidemic if not contained, whereas importations after local expansion has begun are less impactful [51]. Using an example of pandemic influenza, they estimated that a 90% reduction of imports would delay the first importation event by 11.5 days. Based on routine surveillance data from FOPH, we previously extrapolated a total of 6,211 and 37,061 imported cases in Switzerland during summer 2020 and 2021, respectively. Using genomic data to estimate the number of imports might have the advantage of being less prone to the bias in routine surveillance data. Other studies also using phylogenetics estimated the number of imported infections during the early phase of the SARS-CoV-2 pandemic. For example, 13 and 101 introductions were estimated to South Africa over two and eight months [26,52], 120 introductions were estimated in Boston over three months [23], and more than 1,000 introductions were estimated to the UK over three months [6]. During summer 2020, we estimated 34 to 291 introductions of the SARS-CoV-2 variant EU1 to Switzerland over four months [3]. Phylogenetics offers an advantage in estimating imports by leveraging sequence data that was readily produced by many countries in the pandemic, but can be limited by insufficient coverage to detect importations, fluctuations in coverage, and dependence on other countries to also sequence sufficiently. Methods such as that employed by Pung et al. in Singapore can incorporate detailed case finding and contact tracing data to break down the impact of different measures even further, but the availability of such data varies widely across countries and pandemic stage [53].

Global genomic surveillance is essential to monitor the emergence and spread of VoCs. As of February 2023, more than 14 million SARS-CoV-2 sequences have been submitted to GISAID [33]. This effort facilitated the early identification of several VoCs, such as Omicron in November 2021 [52]. Early detection of variants with substantial immune evasion or altered severity can inform policy makers to adjust control measures, vaccination programs, and health systems. For example, several countries imposed controversial travel bans for visitors from South Africa to prevent importation of Omicron [54]. In our analysis, we found that complete border closures following warnings of VoCs have limited impact and delay their spread by a couple of days only. Hence, travel bans and any time they may buy for certain interventions, such as increasing the uptake of booster vaccines, have to be carefully balanced against the societal and economic costs that accompany them. Similar to our findings, McCrone et al. reported that control measures that had just been introduced in response to warnings about Delta were late, as introductions have already occurred to other countries [24]. In addition to studying importation and exportation events of VoCs, it is important to better understand the spread of VoCs in the local context. Variations in naturally-acquired and vaccine elicited levels of immunity, local control measures, mobility, and behavior can strongly influence the local spread of VoCs. Taking these factors into account will be critical to inform country-specific strategies to respond to the emergence of new VoCs.

Integrating phylogenetic analyses with dynamic transmission models can provide critical insights into the importation and early spread of SARS-CoV-2 VoCs, and how they are impacted by different intervention scenarios. In this study, we showed that border closures would have had a limited impact on the spread of Alpha and Delta in Switzerland. In contrast, increased surveillance of travelers can potentially delay the spread of VoCs by several weeks, which can buy time for health systems to prepare for new epidemic waves.

Supporting information

S1 File. Method of the phylogenetic approach and supporting figures for the main text.

(DOCX)

S1 Table. Data availability statement to use data from GISAID.

(DOCX)

S2 Table. Accession number for SARS-CoV-2 genomes sequenced in Switzerland.

(PDF)

Acknowledgments

We gratefully acknowledge all data contributors, i.e., the authors and their originating laboratories responsible for obtaining the specimens, and their submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is based. We also gratefully acknowledge and thank all labs around the world that have collected and shared SARS-CoV-2 sequences we used in our study. A complete list of the labs that generated the data we used from GISAID can be found at doi.org/10.55876/gis8.221003xn. In particular, we want to especially thank the Swiss laboratories that perform SARS-CoV-2 sequencing, namely ‘Hôpitaux Universitaires Genève’ (HUG), the ‘Centre hospitalier universitaire vaudois’ (CHUV), the ‘Universitätsspital Basel’, the ‘Institut für Infektionskrankheiten’ (IFIK) of the University of Bern, ‘Institute of Medical Virology’ (IMV) of the University of Zurich, the ‘Ente Ospedaliero Cantonale’ (EOC) in Bellinzona, and ‘Institut Central des Hôpitaux du Valais’.

Data Availability

The data of confirmed SARS-CoV-2 cases are openly shared by the Swiss Federal Office of Public Health (FOPH) and sequence data are available on GISAID after registration, as EPI_SET_221003xn (S1 Table). Most Swiss sequences (93%) that we used are also available openly, see S2 Table for list of accession numbers. Our code is openly accessible in the following repositories: github.com/ISPMBern/voc_imports_ch (https://doi.org/10.5281/zenodo.7994708) for the transmission modeling, https://github.com/emmahodcroft/ncov_2021/tree/random_context_reduce (https://doi.org/10.5281/zenodo.7970773) for the phylogenetic analysis and github.com/emmahodcroft/Intros-CH-AlphaDelta (https://doi.org/10.5281/zenodo.7970756) for the inference of importations.

Funding Statement

MLR and CLA were supported by the European Union’s Horizon 2020 research and innovation program - project EpiPose (No 101003688). CLA and EBH received funding from the Swiss National Science Foundation (No 196046). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Decision Letter 0

Ronald Swanstrom, Shuo Su

3 Apr 2023

Dear MSc Reichmuth,

Thank you very much for submitting your manuscript "Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: phylogenetic analysis and intervention scenarios" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Shuo Su

Academic Editor

PLOS Pathogens

Ronald Swanstrom

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: This paper attempts to combine compartmental models of epidemiology and transmission graphs derived from phylogenetic

analysis to test various policy counterfactuals and their effects. In general, the paper is vague on details regarding

the phylogenetic analysis, and therefore fails to be a convincing argument. My specific issues are detailed below, but

in short the authors took an inferred phylogenetic tree as ground truth to perform their analyses. While this is a

normal assumption in many other papers, it is particularly problematic when applied to SARS-CoV-2 data. Therefore, I

request that the authors improve the robustness of their analysis by considering phylogenetic uncertainty (some

suggestions have been listed below).

I cannot speak to the portion of analysis based on compartmental models, however it seems to my eyes to also be quite

vague on details.

At the moment, there is nothing to my eyes that would constitute unfixable errors in methodology. Furthermore, the

testing of policy interventions is self-evidently valuable, regardless of the particular conclusions. However, the

amount of work required to make those conclusions robust and reliable might be significant, as the authors made

assumptions about their data (that phylogenetic analysis is reliable in this case) which are not born out by prior work.

Reviewer #2: Summary

The authors combine phylogenetic inference and mathematical models to explore the impact of border closure to prevent the spread of SARS-CoV-2 variants in Switzerland. The phylogenetic inference was performed on sequences from the Alpha and Delta variant. By inferring ancestral states, the authors could estimate a conservative and a liberal number of introductions. They then used these estimates to parameterise an SEIR transmission model with two viral strains (a resident and a mutant) and performed counterfactual scenarios to explore the impact on the time until variant dominance of closing border for a given duration or increasing surveillance.

I found the phylogenetic inference impressive and the mathematical modelling robust. The combination of the two is promising and, generally, the authors are also very aware of the limitations of their approach. However, I still have a few concerns or questions. The main suggestion is to better demonstrate the added value of combining phylogenetic inference and compartmental modelling, for instance by performing sensitvity analyses but also by better discussing earlier studies on similar topics.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: The citations in the PDF provided are essentially dead links. If clicked on, the link directs the user to a Zotero page

with no meaningful information. This should be corrected before the final publication, and it makes reading the paper

and checking the references a bit difficult.

The description of the conservative and liberal approaches to count imports is quite vague. For the conservative

estimate, it isn't clear what "counts" as a subtree. The Figure 1A suggests that it is some maximal clade, which

contains all the Swiss sequences. However, if this is the case, then by

> When Swiss and non-Swiss sequences intermix within a subtree, the conservative approach count[s] this as only one

> import.

the conservative estimate would always be 1, for any tree. However, Figure 4A and B show conservative counts much higher

than 1, so there must be some method to picking the subtrees other than "maximal clades" which is not described in the

paper.

The liberal approach seems to be more clear, as it seems to be counting the number of "monophyletic" clades in the tree,

and probably includes individual tips. In this case, it seems it would be the minimum number of clades s.t. all clades

are "monophyletic" and all Swiss sequences are accounted for. Of course, this definition can be made more rigorous by

describing the clade as sets or partitions on tips. Nonetheless, as this metric is an important result of the paper, a

explicit and rigorous definition should be presented.

Secondly, the above definitions are in conflict with the first sentence:

> We inferred an import whenever a node without Swiss sequences led to a node with Swiss sequences.

Which is

a) very vague as there is no description of how internal nodes are assigned to be either Swiss or non-Swiss and

b) contradictory with later definitions.

Basically, the section describing this section needs to be made much more clear.

However, regardless of the particular definition of conservative and liberal estimates of imports, performing this

operation on a particular tree is methodologically questionable. Recall that phylogenetic analysis of SARS-CoV-2 data is

difficult[1], and the phylogenies are unstable [2]. Sequences which are sampled close together often differ by only a

sites, leading to the case where the support for any _particular_ phylogeny is not very strong. Furthermore, sequencing

error from some labs might bias the results in this case [3]. The phylogeny in this paper appears to be constructed via

the Nextstrain pipeline [4], which is well regarded. However, this pipeline doesn't escape the fundamental problems that

there doesn't seem to be enough signal to reliably resolve the phylogeny to the detail required for this paper.

This difficulty in resolving the fine grained phylogenetic relationships between sequences is a particular issue for

this paper, as a core metric relies on accurately and reliably being able to resolve these relationships. I hesitate to

give a specific instruction to fix methodology, but in this case _some_ level of uncertainty analysis must be done. The

authors could construct a tree set like in [1], or to sample trees from the posterior in some Bayesian inference program

(such as BEAST or RevBayes). In either case, the authors should rerun their analyses on these sample trees, in order to

ensure that the results are stable. It is possible that the conclusions of this paper hold, however it is not clear at

this point that the conclusions of this paper are dependant on a particular (and possibly incorrect) tree.

[1]: https://doi.org/10.1093/molbev/msaa314

[2]: https://doi.org/10.1371/journal.pgen.1009175

[3]: https://virological.org/t/issues-with-sars-cov-2-sequencing-data/473

[4]: Though this is never explicitly stated, and can only be inferred via a reference to another paper. However, that

paper has procedures for sub sampling the dataset which do not directly translate to the subject matter at hand. In

particular, the number of sequences reported to be in the tree in Hodcraft 2021 is different than then number of

sequences reported in this paper.

Reviewer #2: 1) Sampling rate

The authors are working with an absolute number of introductions in the country. Intuitively, this number seems very dependent on the sampling rate (proportion of the infections sequenced), although potentially not in a linear way. Furthermore, as the authors accurately acknowledge in the Discussion, the nature of the dataset used as a reference may also affect the results. On both these topics, the sensitivity analyses performed seem a bit light (or absent).

First, the authors could subsample their dataset to see how the number of introductions scales with the subsampling. I think this can be done easily because it does not require to re-infer the phylogeny. Second, the authors could try a few different reference datasets to show that their estimates remain unaffected. For the latter, the computational burden is higher so perhaps a few datasets will suffice.

2) Model results

One of the main results is that the model underestimates the increase in variant frequency, even when using the liberal definition of importation events. This lag is less pronounced for Delta than for Alpha. In my opinion, this can either come from the importation rate or from some of the model specifications. At any rate, the origin of this mismatch and why it is more pronounced for the Alpha variant should be explored more thoroughly. One possibility could be to use the observed data to infer the VOC import rate instead of fixing it (unless another parameter seems less reliable).

3) Model parameterisation

As earlier studies, e.g. Du Plessis et al (Ref. 6 in the manuscript, which could perhaps be discussed some more), the authors can infer the number but also the date of VOC introduction. I wonder if turning this into a constant input rate is not throwing some of the information away. Put differently, if the goal is to infer such a rate while all the other model parameters are known (see Table 1), then why not use a more appropriate dataset and, for instance, try to fit the proportion curves?

3) Insights

Overall, I found that the discussion about the insights from the study was somehow limited. The most interesting bit was the second to last paragraph from line 361 about Omicron. One way to improve the discussion could be to refer to earlier studies. For instance, a quick search online pointed towards a paper from Scalia Tomba & Wallinga (2008, Math Biosci) with an eloquent title: "A simple explanation for the low impact of border control as a countermeasure to the spread of an infectious disease". More recently, Pung et al (2023, BMC Med) seem to have developed a more detailed model addressing similar questions.

Related to this point, showing the added value of fitting the number of introductions from the sequence data rather than on the relative variant proportion might help. For this, discussing differences with other studies that performed similar inferences, e.g. Du Plessis et al in England, seems important.

4) Data sharing

Before criticising, I want to stress that the authors made impressive efforts to share the code they developed! Perhaps they could also consider a more permanent repository than GitHub (either PLoS Pathogens supplementary materials or a repository with a DOI).

However, given the current context about GISAID usage, it seems important to check that the laboratories who contributed essential data to this work (so the Swiss Alpha and Delta sequences) were contacted to be involved in the study or that there is a national agreement about genetic data usage (akin to the UK genomics consortium). In any case, the sentence in line 388 suggesting that the data is openly shared by GISAID is inaccurate: there are restrictions to this use.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: Honestly, this section is quite short. I stopped adding to it after I realized that significant changes to the methodology would have to be made.

Page 4, starting on 116:

> When Swiss and non-Swiss sequences intermix within a subtree, the conservative approach counted this as only one

> import, with further non-Swiss sequences assumed to originate from parallel evolution outside of Switzerland or

> exports from Switzerland (Fig 1A).

The language here is a bit awkward, and I think there are some error in tenses. "Intermix" is present tense, but

"counted" is past tense, and they should be the same tense, probably present tense.

Page 4, starting on 119: Importation -> import

Page 7, line 177: Importation -> import or "simulated the importation" -> "simulated importation"

Reviewer #2: line 48: the term "lockdown" should be handled with care because it has different meanings in different countries or contexts. Perhaps the authors should spend a bit more time defining it carefully to avoid potential misunderstandings.

line 157: I think kappa estimates a growth advantage rather than a transmission advantage (if a variant causes longer infections with a similar transmission rate it would also be captured). Perhaps update the formulation?

Table 1: I did not understand how the testing delay came into the model (to go from "tested" to "recovered").

page 9: It seems important to mention that the Alpha variant was first detected and studied because of the S-target gene failure. Sequencing confirmed the detection (showing that it was a variant) and was used later to study variant spread.

Figure 5: the nature of the x-axis is unclear (is it how long the border is closed?). Also, having all three panels on a line would help comparisons. Finally, I do not understand why panel c could not be a deterministic model as well.

line 301: specify against which strain the transmission advantage is computed.

Reference 37 (about computing variant growth advantage) is missing.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ben Bettisworth

Reviewer #2: Yes: Samuel Alizon

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Ronald Swanstrom, Shuo Su

20 Jun 2023

Dear MSc Reichmuth,

Thank you very much for submitting your manuscript "Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: phylogenetic analysis and intervention scenarios" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Shuo Su

Academic Editor

PLOS Pathogens

Ronald Swanstrom

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The authors have done an excellent job addressing the (possibly overly callous on my part) comments from the reviewers.

At this time, I only have minor issues with the added explanation regarding the explanation of how imports are

calculated.

Reviewer #2: I thank the authors for carefully answering my concerns. I found the new sensitivity analysis on the importance of sampling particularly thorough. The model specifications are also clearer and I realised that I misunderstood the definition of the import rate. Overall, I think the authors now better show what the phylogenetic component brings to these counterfactual models.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: All of my major concerns have been addressed. I quite like the addition of the sensitivity analysis, and I think it

greatly improves the reliability of the results presented in the paper.

Reviewer #2: My sole suggestion is still about this sampling rate because, if I think I now understand how it plays in the model, it might still not be the case. More precisely, in the Methods, \\omega_t is never really properly defined. All that is said is that it "was based on the daily number of estimated imports" (page 5). Introducing it from the section "Phylogenetic analysis" (pages 3-4) would help insist on its added value. Furthermore, this time-varying property could also be underlined in the results because currently the authors only mention the total number of introductions ("we found 1,038 and 1,347 imports of Alpha and Delta into Switzerland, respectively", page 8). How did this input rate vary with time? Was it proportional to the circulation of the VOC in Europe or in the world? Addressing these questions by leaning on the (beautiful) Figure 4 would further show the importance of phylogenetic insights.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: The added explanation for how the number of imports is an improvement, but I still feel it is a bit unclear, especially

after reading the supplement. However, I think that this can be fixed easily. On line 37:

"we collapsed subtrees that contain only sequences from a single country into the parental node recursively" ->

"we collapsed subtrees which contain only sequences from a single country into the parent node to form a polytomy. This

process was repeated in a recursive 'bottom-up' fashion, such that every node eligible for collapse was collapsed."

And add "we classified inner nodes based on the composition of their _direct_ children, after collapsing subtrees into

polytomies" (or something like that, I don't mean to dictate your voice) to the same paragraph.

Reviewer #2: page 7: The SGTF sentence might be better suited in the introduction but it's up to you.

page 10: Do you mean that Tomba and Wallinga (2008) showed that you need a 90% or greater reduction in imports so that the time to dominance can be delayed by more than a week?

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Samuel Alizon

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Decision Letter 2

Ronald Swanstrom, Shuo Su

11 Jul 2023

Dear MSc Reichmuth,

We are pleased to inform you that your manuscript 'Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: phylogenetic analysis and intervention scenarios' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Shuo Su

Academic Editor

PLOS Pathogens

Ronald Swanstrom

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: I have no further issue with the manuscript, and I think it is ready for publication.

Reviewer #2: (No Response)

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Samuel Alizon

Acceptance letter

Ronald Swanstrom, Shuo Su

6 Aug 2023

Dear MSc Reichmuth,

We are delighted to inform you that your manuscript, "Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: phylogenetic analysis and intervention scenarios," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Method of the phylogenetic approach and supporting figures for the main text.

    (DOCX)

    S1 Table. Data availability statement to use data from GISAID.

    (DOCX)

    S2 Table. Accession number for SARS-CoV-2 genomes sequenced in Switzerland.

    (PDF)

    Attachment

    Submitted filename: Response Imports of variants.pdf

    Attachment

    Submitted filename: Response Letter.pdf

    Data Availability Statement

    The data of confirmed SARS-CoV-2 cases are openly shared by the Swiss Federal Office of Public Health (FOPH) and sequence data are available on GISAID after registration, as EPI_SET_221003xn (S1 Table). Most Swiss sequences (93%) that we used are also available openly, see S2 Table for list of accession numbers. Our code is openly accessible in the following repositories: github.com/ISPMBern/voc_imports_ch (https://doi.org/10.5281/zenodo.7994708) for the transmission modeling, https://github.com/emmahodcroft/ncov_2021/tree/random_context_reduce (https://doi.org/10.5281/zenodo.7970773) for the phylogenetic analysis and github.com/emmahodcroft/Intros-CH-AlphaDelta (https://doi.org/10.5281/zenodo.7970756) for the inference of importations.


    Articles from PLOS Pathogens are provided here courtesy of PLOS

    RESOURCES